Candriam S.C.A. Kodiak Sciences Inc. Transaction History

Candriam S.C.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.09 - $89.45 $235,288 - $2.97 Million	-33,186 Closed	0 $0
Q2 2021 Jul 20, 2021	SELL	$77.2 - $126.54 $8.68 Million - $14.2 Million	-112,483 Reduced 77.22%	33,186 $3.09 Million
Q4 2020 Jan 22, 2021	SELL	$60.78 - $154.03 $13.4 Million - $34 Million	-220,679 Reduced 60.24%	145,669 $21.4 Million
Q3 2020 Oct 19, 2020	SELL	$45.05 - $59.27 $1.45 Million - $1.91 Million	-32,159 Reduced 8.07%	366,348 $21.7 Million
Q2 2020 Jul 23, 2020	BUY	$42.74 - $66.25 $16.4 Million - $25.5 Million	384,160 Added 2677.63%	398,507 $21.6 Million
Q4 2019 Jan 21, 2020	SELL	$13.9 - $76.65 $3.34 Million - $18.4 Million	-240,153 Reduced 94.36%	14,347 $1,000
Q3 2019 Oct 21, 2019	BUY	$10.24 - $17.57 $2.61 Million - $4.47 Million	254,500 New	254,500 $4,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $276M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.